Expression of Fibroblast Growth Factor Receptor 3 in the Recurrence of Non-Muscle-Invasive Urothelial Carcinoma of the Bladder.
- Author:
Young Hee MAENG
1
;
Su Yong EUN
;
Jung Sik HUH
Author Information
- Publication Type:Original Article
- Keywords: Carcinoma, transitional cell; Fibroblast growth factor receptor 3; p53 genes; Recurrence
- MeSH: Carcinoma, Transitional Cell; Cytoplasm; Fibroblast Growth Factors; Fibroblasts; Genes, p53; Humans; Immunohistochemistry; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Recurrence; Urinary Bladder; Urinary Bladder Neoplasms
- From:Korean Journal of Urology 2010;51(2):94-100
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The fibroblast growth factor receptor 3 (FGFR3) gene is known to be frequently mutated in noninvasive urothelial carcinomas of the bladder. In this study, we investigated the expression of FGFR3, Ki-67, and p53 in bladder cancers and the effects of expression on tumor recurrence. MATERIALS AND METHODS: Fifty-five cases of primary bladder cancer were examined by immunohistochemistry. The relationship of these markers with various clinicopathological factors, including recurrence, was assessed. RESULTS: Positivity for cytoplasmic FGFR3 (FGFR3-c) was associated with a lower cancer grade (p=0.022) and stage (p=0.011). Recurrence was more frequent in patients with a higher stage, negative FGFR3-c, and high Ki-67 expression. According to univariate analysis, predictors of recurrence-free survival included the following: age, stage, FGFR-c, Ki-67, and p53. However, none of these was independent from the other parameters in multivariate studies. CONCLUSIONS: The immunohistochemical expression of FGFR3 is not only one of the characteristic features of lower-grade and lower-stage urothelial carcinoma but also a possible marker in predicting disease recurrence.
